MAYO CLINIC Evaluation and Management of Hypertension in Women



Vesna D. Garovic, M.D. Moscow, Russia, December 2016

©2016 MFMER | 3508058-1

Women are not small men

"There is nothing as powerful as an idea whose time has come."

Victor Hugo, 1877



Objectives

- Update current recommendations on BP measurement and confirmation of HTN
- HTN in women throughout their reproductive age
- Review current recommendations regarding BP treatment goals
 - Discuss the Systolic Hypertension Intervention Trial (SPRINT)
- Sex-specific hypertension issues



Diagnosis of Hypertension Office BP Measurement

- No caffeine, nicotine, exercise for 30 min
- Empty bladder
- Seated quietly for 5 minutes
- Feet on floor, back supported, arm supported at heart level
- Appropriate cuff size
- No talking during measurement





Office Blood Pressure Measurement

Automatic (oscillometric)

Measurement using electronic (oscillometric) upper arm devices is preferred to auscultatory devices



Obtain at least 3 readings and average the last 2.



WHL, WHO, CHEP -2015

Office Blood Pressure Measurement Office Automated (Unattended)

Unattended automated procedure is ideal





Initial BP after 1 minute.

6 measurements are made at 1 minute intervals – device averages last 5 readings



HTN Treatment 2016 Confirmation of Diagnosis

- U.S. Preventive Services Task Force: High Blood Pressure in Adults: Screening – Statement
- ABPM (self-BP monitoring) better predictor than Office BP of fatal and non-fatal CVD
 - <u>ABPM is the reference standard for confirming</u> the diagnosis of HTN
 - Good quality evidence suggests that confirmation using self- BP monitoring may also be acceptable



HTN Treatment 2016 Definition of HTN by Method of Measurement

<u>Method</u>	<u>Equivalent BP (mm Hg)</u>		
Quality manual office BP AOBP (attended)	140/90		
AOBP (unattended)	135/85		
Home BP (3-7 days)	135/85		
24 hour ABPM:			
Awake	135/85		
Asleep	120/70		
24-Hour	130/80		

MAYO CLINIC Family Practice 2011;28:110, J Hypertens 2013;31:1731, Hypertension 2010;28:703

HTN Treatment 2016 Home Monitoring for HTN Follow-up

- Improves adherence/cost of treatment
- Identifies white-coat and masked effects
 - Appropriate training under medical supervision
 - AHA guidelines

MAYC

 Twice daily measurements (morning and evening – 2 readings averaged) for 3-7 days prior to each office visit

HTN Treatment 2016 Take Home Points

- Automated methods are preferred over the manual method for office BP measurement
- 24-hour ABPM is the reference standard for confirming the diagnosis of HTN
- **Self-monitoring** is a suitable alternative for confirming HTN and SOC for follow-up care



Sex Differences in CV System

Anatomy: ↓ LV mass, LA, vessel size

CV function: \downarrow 10% stroke volume, \uparrow HR 3-5 bpm, \uparrow EF; longer QTc; Hormone effects: on ECG, hematological indices; more prone to orthostatic hypotension, syncope

Physiology: \downarrow sympathetic, \uparrow parasympathetic activity; RAAS activity

Stress test: ↑ HR, CO, and SVR, increase in BP

NO SEX-SPECIFIC GUIDLEINES!!!



Sex-specific Risk Factors

- Oral contraceptives
- Pregnancy
- Preeclampsia and gestational DM
- HRT
- Stronger, more prevalent in women, risk factors
 - Hypertension
 - DM
 - Atrial fibrillation
 - Migraine with aura




Oral Contraceptives and Hypertension

- OCs frequently cause a mild elevation in blood pressure within the normal range
- Overt hypertension can occur
- Early reports: preparations containing at least 50 mcg of estrogen and 1 to 4 mg of progestin, HTN incidence 5%
- Nurses' Health Study: RR of HTN compared with women who never used OC: 1.8 for current users and 1.2 for previous users
- Hypertensive OC users *încreased* risk of MI and stroke relative to nonusers



Hypertension recognized within 12 months of second consecutive elevated blood pressure, by patient age.




p<.001 for all comparisons

Julie Schmittdiel et al. Hypertension. 2011;57:717-722



Copyright © American Heart Association, Inc. All rights reserved.


Patterns of change in weight in women between prepregnancy and 3 months postpartum and between 3 and 12 months postpartum.



Simone Kew et al. Dia Care 2014;37:1998-2006




Mean adjusted levels in each group for the following cardiometabolic risk factors at 3 and 12 months postpartum: (A) systolic blood pressure, (B) diastolic blood pressure, (C) HOMA-IR, (D) adiponectin, (E) LDL cholesterol, and (F) apoB.



Simone Kew et al. Dia Care 2014;37:1998-2006



HRs of CHD associated with the presence of ≥ 1 components of the metabolic syndrome



Components of the ATP III Metabolic Syndrome

Ann Marie McNeill et al. Dia Care 2005;28:385-390

Summary Recommendations Women <50 years

- Closely monitor BP during and after pregnancy
- Yearly assessment of BP, lipids, FBG, and BMI

ACOG, Task force on HTN in pregnancy. Obstet Gynecol 2013

- Treatment according to current guidelines
- Life-style modifications
 At present, suboptimal identification and treatment of CVD risks



Postmenopausal Hypertension

- After menopause, BP increases to levels
 > in men
- Lack of estrogen
 - ↓ endothelial nitric oxide production



Sex Differences in HTN

- Compared to men, women are:
 - More aware of their diagnoses (85 vs. 80%)
 - More compliant (81 vs. 71%)
 - Better HTN control (55 vs 49%)

NCHS, 2015

More "white coat" HTN (43 vs 34%)



Sex-specific Responses to HTN Therapy

- ALLHAT: amlodipine vs. lisinopril, ↑ reduction in BP, ↓ stroke rate
- VALUE: amlodipine vs. valsartan, ↓ CVD morbidity and mortality
- Adverse effects
 - More hypokalemia/hyponatremia on diuretics
 - ACE-related cough
 - CCB-related peripheral edema



Treatment Goals

Condition

- HTN ISH
- **Diabetes/CKD**
- High-risk CAD
- Proteinuria (>1 gm/24 Hr)

Systolic HF

BP Goal (mm Hg)

- <140/90
- <140
- <130/80
- <130/80
- <125/85
- <120/80



Circulation 2007;115:2761-2788; National Kidney Foundation; JNC 7

Hypertension 2016 New Treatment Goals – JNC 8

Age <60 years, DM, CKD SBP <140 and DBP <90

Age ≥60 years SBP <150 and DBP <90



JAMA 2014;311(5):507-520

Original Article A Randomized Trial of Intensive versus Standard Blood-Pressure Control

The SPRINT Research Group

N Engl J Med Volume 373(22):2103-2116 November 26, 2015





A Randomized Trial of Intensive versus Standard Blood-Pressure Control - SPRINT

Main inclusion criteria:

- U.S. adults \geq 50 years old
- SBP 130 180 mm Hg (treated or untreated)
- High CVD risk:
 - Clinical or subclinical CVD (previous MI, PCI, CABG, CEA, PAD, AAA, reduced ABI, CAC score ≥400, LVH)


N Engl J Med 373(22):2103-2116

November 26, 2015

- CKD (eGFR 20 59 mL/min/1.73 m2
- 10-year FRS ≥15%
- Age ≥75 years
- Main exclusion criteria:
- Diabetes (ACCORD) or prior stroke (SPS-3)



Systolic Blood Pressure Intervention Trial 102 SPRINT Clinical Centers



Primary composite outcome: MI, non-MI ACS, stroke, HF, death from CV cause



Wright JT et al. NEJM 2015;373:2103-16

Systolic Blood Pressure Intervention Trial Characteristics of the Study Sample


<u>Criterion for ↑ CV risk</u>	<u>Intensive</u>	<u>Standard</u>
Age ≥75 year	28.2%	28.2%
CKD	28.4%	28.1%
CVD	20.1%	20.0%
FRS ≥15%	61.4%	61.2%
Age: Overall	67.9 yr	67.9 yr
Race: Blacks	29.5%	30.4%
Female sex	36%	35.2%

Baseline BP 139.7/78.2 mm Hg on 1.8 meds

Wright JT et al. NEJM 2015;373:2103-16




Achieved Systolic Blood Pressure




SPRINT Primary Outcome MI, ACS, stroke, HF, CV death

1.65%/yr vs 2.19% /yr



 The SPRINT Research Group. N Engl J Med 2015;373:2103-2116

SPRINT: All-cause Mortality Cumulative Hazard



The SPRINT Research Group. N Engl J Med 2015;373:2112



SPRINT Components of the Primary Outcome

	Intens	ive Rx	Standard Rx			
	No of Events	Rate, %/year	No of Events	Rate, %/year	HR (95% CI)	
MI	97	.65	116	.78	.83 (.64; 1.09)	
Non-MI ACS	40	.27	40	.27	1.00 (.64; 1.55)	
Stroke	62	.41	70	.47	.89 (.63; 1.25)	
HF	62	.41	100	.67	.62 (.45; .84)	
CVD death	37	.25	65	.43	.57 (.38; .85)	



Systolic Blood Pressure Intervention Trial SPRINT

Serious AE:

- Overall: 38.3% intensive vs 37.1% standard
- Related: 4.7% intensive vs 2.1% standard
 - Syncope (3.5% vs 2.4%),
 - Hypotension (3.4% vs 2.0%)
 - AKI (4.4% vs 2.6%)
 - Electrolyte abnormalities:
 - Hyponatremia (3.8% vs 2.1%)
 Hypernatremia (0.1 vs 0)
 - Hypokalemia (2.4% vs 1.6%)



Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus The ACCORD BP Study Group

Main inclusion criteria:


- US and Canada
- ≥40 y/o with CVD or
- ≥55 y/o with substantial atherosclerosis, albuminuria, LVH or two CV risk factors (dyslipidemia, HTN, smoking, obesity)

Main exclusion criterion:

• Serum Cr ≥1.5 mg/dL



Action to Control CV Risk in Diabetes 77 ACCORD BP Clinical Centers





N Engl J Med. 2010;362:1575-85

Primary and Secondary Outcomes

	Intensive Events (%/yr)	Standard Events (%/yr)	HR (95% CI)	Р
	(/0/ y1)	(/0/ y1)		
Primary	208 (1.87)	237 (2.09)	0.89 (0.73-1.07)	0.20
Total Mortality	150 (1.28)	144 (1.19)	1.07 (0.85-1.35)	0.55
Cardiovascular Deaths	60 (0.52)	58 (0.49)	1.06 (0.74-1.52)	0.74
Nonfatal MI	126 (1.13)	146 (1.28)	0.87 (0.68-1.10)	0.25
Nonfatal Stroke	34 (0.30)	55 (0.47)	0.63 (0.41-0.97)	0.03
Total Stroke	36 (0.32)	62 (0.53)	0.59 (0.39-0.89)	0.01

N Engl J Med. 2010;362:1575-85


MAYO CLINIC

ᢧᠮ

ACCORD vs SPRINT

- Primary outcome included higher proportion of events less sensitive to BP reduction (did not include HF, a more BP sensitive event)
- Average age younger in ACCORD 62 y/o vs 68 y/o in SPRINT
- ACCORD used HCTZ, SPRINT used Chlorthalidone
- Female sex 50% in ACCORD vs 35% in SPRINT






Prevalence of high blood pressure in adults ≥20 years of age by age and sex (National Health and Nutrition Examination Survey: 2005–2008).

Writing Group Members et al. Circulation. 2012;125:e2-e220



Proportion of women in RCTs compared with the proportion of women among the population with a given disease and proportion of women among deaths attributable to the disease.



2010;3:135-142



SPRINT Redefining Blood Pressure Targets

- Lower targets (<130 mm Hg?) for:
 - Adults ≥ 75 y/o (meet entry criteria, non-frail)
 - Adults \geq 50 y/o with: (meet entry criteria)
 - Clinical or subclinical CVD
 - 10-yr FRS of ≥15%
 - CKD with eGFR 20-59 mL/min
 - Extend SPRINT to <u>younger persons at high CV risk</u> and to <u>diabetics</u> ???
- New guidelines likely will develop a risk-based method for selecting BP thresholds
- Sex-based, in women HTN
 - Under-recognized
 - Under-treated



HTN Treatment 2016 Management

- Set BP goal
- Begin Treatment
 - Lifestyle changes
 - Antihypertensive drug therapy



My Approach to Hypertension -Juggling Guidelines with Emerging Evidence-

- Based on epidemiological data, BP 120/80 mm Hg <u>optimal</u> for women who tolerate that BP
- WHI: women with prehypertension, intermediate adverse outcomes between normotensive and hypertensive
- If intensifying, "start low and go slow"; shared decision making
- Future studies to address the applicability of SPRINT data
- Sex-specific risk factors



HTN Treatment 2016 Take Home Points

- The current BP goal of <140/90 mm Hg (150/90 in persons ≥ 60 y/o without DM or CKD) will likely be modified in updated guidelines from the AHA/ACC due out later this year.
 - BP goals will be based on a determination of individual risk, comorbidities, polypharmacy and employ shared-decision making
 - Sex-specific factors
 - Identifying and treating HTN in premenopausal women



Questions?





©2016 MFMER | 3508058-43

CV Event Rates in ACCORD BP and SPRINT

	Standard (%	% per yr)	Intensive (% per yr)		Hazard Ratio	
Event	ACCORD	SPRINT	ACCORD	SPRINT	ACCORD	SPRINT
All Deaths	1.19	1.40	1.28	1.03	1.07	0.73
Death from CV causes	0.49	0.43	0.52	0.25	1.06	0.57
Nonfatal MI	1.28	0.77	1.13	0.63	0.87	0.82
All Stroke	0.53	0.47	0.32	0.41	0.59	0.89
Nonfatal Stroke	0.47	0.45	0.30	0.39	0.63	0.88
All HF	0.78	0.67	0.73	0.41	0.94	0.62
ACCORD Primary Outcome*	2.09	1.52	1.87	1.15	0.88	0.75

*Results for application of the ACCORD composite in both SPRINT and ACCORD.



Cushman et al. Hypertension 2016;67:263-265

A Randomized Trial of Intensive versus Standard Blood-Pressure Control - SPRINT

Main exclusion criteria:

- Diabetes
- Prior stroke
- PCKD
- HF (symptoms or EF<35%)
- Proteinuria >1g/d
- SBP >180 mm Hg
- CKD with eGFR <20 cc/min
- Nursing home patient or dementia



Systolic Blood Pressure Intervention Trial SPRINT

- Representative medications from all major classes provided at no cost to participants
- Recommended to use drugs with strongest evidence for CVD outcomes: thiazides (chlorthalidone), CCB (amlodipine), ACEI/ARB and for comorbidities (e.g., ACEI/ARB in CKD).
- Standardized BP measurements: Omron, average of 3 seated readings after 5 minute rest
- Monthly visits until goal achieved:
 - Standard group: medication reduction if SBP< 135 mm Hg (goal 135-139 mm Hg)
 - DBP goal <90 mm Hg

